Header Logo

Connection

Kamyar Kalantar-Zadeh M.D. to Hematinics

Back to Details
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Hematinics.
Kamyar Kalantar-Zadeh M.D.
Connection Strength
5.090
Hematinics
  1. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther. 2021 01; 38(1):52-75.
    View in: PubMed
    Score: 0.687
  2. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol. 2017; 45(3):235-247.
    View in: PubMed
    Score: 0.530
  3. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing. Clin J Am Soc Nephrol. 2015 Oct 07; 10(10):1814-21.
    View in: PubMed
    Score: 0.479
  4. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013 Jul; 28(7):1936-45.
    View in: PubMed
    Score: 0.393
  5. Association of pre-transplant erythropoiesis-stimulating agent responsiveness with post-transplant outcomes. Nephrol Dial Transplant. 2012 Aug; 27(8):3345-51.
    View in: PubMed
    Score: 0.380
  6. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011 Aug; 6(8):1973-81.
    View in: PubMed
    Score: 0.361
  7. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010 Feb 18; 362(7):654; author reply 655.
    View in: PubMed
    Score: 0.327
  8. Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009 Dec; 35 Suppl 2:14-24.
    View in: PubMed
    Score: 0.322
  9. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009 May; 53(5):823-34.
    View in: PubMed
    Score: 0.308
  10. Emerging challenges of anemia management in CKD. Adv Chronic Kidney Dis. 2009 Mar; 16(2):74-5.
    View in: PubMed
    Score: 0.306
  11. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis. 2009 Mar; 16(2):143-51.
    View in: PubMed
    Score: 0.306
  12. Epoetin dosing and dialysis facility ownership. JAMA. 2007 Aug 22; 298(8):862; author reply 862-3.
    View in: PubMed
    Score: 0.275
  13. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol. 2012; 35(2):198-208.
    View in: PubMed
    Score: 0.094
  14. Erythropoietin in kidney disease and type 2 diabetes. N Engl J Med. 2011 01 27; 364(4):384-5; author reply 385-6.
    View in: PubMed
    Score: 0.087
  15. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009 Mar; 20(3):479-87.
    View in: PubMed
    Score: 0.076
  16. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients? Nephrol News Issues. 2007 Jan; 21(1):34-8.
    View in: PubMed
    Score: 0.066
  17. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006 Sep; 1 Suppl 1:S9-18.
    View in: PubMed
    Score: 0.064
  18. New Options for Iron Supplementation in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2016 Mar; 67(3):367-75.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.